DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF SITAFLOXACIN IN BULK AND PHARMACEUTICAL DOSAGE FORMS
Objective: A simple, specific, and precise reversed phase high performance liquid chromatography method was developed and validated as per the ICH guidelines for the determination of Sitafloxacin in bulk and tablet dosage forms.
Methods: The quantitation was carried out by using Symmetry C18 ((5 Âµm, 100X4.6 mm) column at 300c with Water: Acetonitrile in ratio of 70:30 % V/V as mobile phase. The flow rate is 0.9 mL/min and the estimation was carried out by using PDA detector at 300 nm.
Results: The retention time of Sitafloxacin was 2.198 minutes. The linearity was observed from 5-25 Î¼g/mL with correlation coefficient 0.9999. The LOD and LOQ were found to be 0.429Î¼g/mL and 1.415Î¼g/mL respectively.
Conclusion: The Statistics data for the Sitafloxacin was concluded that the method was found to be simple, reliable, selective, reproducible and accurate. The method was successfully used for quality control analysis of Sitafloxacin in bulk and Pharmaceutical dosage forms.
2. Sean C, Sweetman. Martindale: the complete drug reference, 37th Edn. Pharmaceutical Press: London;2011. p. 360.
3. Milatovic D, Schmitz FJ, Brisse S, Verhoef J, Fluit AC. In vitro activities of sitafloxacin (DU-6859a) and six other Fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000;44:1102-7.
4. Nakane T, S Iyobe, K Sato, S Mitsuhashi. In vitro antibacterial activity of DU-6859a; a new fluoroquinolone. Antimicrob Agents Chemother 1995;39:2822-6.
5. Sato K, K Hoshino, M Tanaka, I Hayakawa, Y Osada. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother 1992;36:1491-8.
6. Tanaka M, K Hoshino, M Hohmura, H Ishida, A Kitamura, K Sato, I Hayakawa, T Nishino. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method. J Antimicrob Chemother 1996;37:1091-102.
7. Giamarellou-Bourboulis EJ, Sambatakou H, Grecka P, Chryssouli Z, Giamarellou H. Sitafloxacin (DU-6859a) and trovafloxacin: postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 1999;34:301-7.
8. Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M. Pharmacokinetics and tolerance of sitafloxacin (DU-6859a), a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother 1995;39:170-4.
9. Hammerschlag MR, CL Hyman, PM Roblin. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:682-3.
10. Huang K, Yang J, Zhang J, Ding Y, Chen L, Xu WY, et al. Determination of sitafloxacin in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2014;957:36-40.
11. ICH Q2 (R1), Validation of Analytical Procedures: Text and Methodology. 2005.